Day: April 6, 2024

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

Written by Customer Service on . Posted in Public Companies.

V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on statin therapy alone led to significant LDL-C reduction vs. clinician-determined usual care (60% vs. 7% respectively)1 A significantly greater proportion of the ASCVD patients receiving Leqvio achieved guideline-recommended LDL-C goal vs. the usual care arm while maintaining adherence to statin treatment1 Results from usual care arm reinforce the urgent need for more aggressive LDL-C lowering in ASCVD patients, 92% of whom did not reach their LDL-C goal with statins alone1 The Leqvio safety profile was consistent with the Phase III clinical studies and long-term open-label extension trials for up to 6 years of treatment1-4 Basel, April 6, 2024 – Novartis today announced new...

Continue reading

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Written by Customer Service on . Posted in Public Companies.

— Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels — — Lp(a) Results Published Simultaneously in the Journal of the American College of Cardiology (JACC) – DUBLIN, Ireland and BRIDGEWATER, N.J., April 06, 2024 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today highlighted two data presentations at ACC.24 describing the effects of VASCEPA®/VAZKEPA® (icosapent ethyl) on reducing MACE (Major Adverse Cardiovascular Events) in patients with baseline high or low Lipoprotein(a) [Lp(a)] levels, as well as reducing the risk of cardiovascular (CV) events in patients irrespective of baseline LDL-C level. The REDUCE-IT analysis results relating Lp(a) concentrations with CV risk were also published online today in the Journal of the American College...

Continue reading

Press Release of Believe’s Ad-Hoc Committee

Press Release of Believe’s Ad-Hoc Committee

Written by Customer Service on . Posted in Mergers And Acquisitions.

Press Release of Believe’s Ad-Hoc Committee Paris, 6 April 2024 –The Ad-Hoc Committee of Believe has taken note of Warner Music Group’s decision not to submit a binding offer for a combination with Believe (“WMG”), as set out in Warner Music Group’s press release of earlier today. The Ad-Hoc Committee will review the situation with all interested parties (including the Consortium composed of EQT, TCV and Mr Denis Ladegaillerie, as well as the historical shareholders of Believe1) to determine next steps in relation to the possible evolution of the Company’s control and will inform the market accordingly. ***** About BelieveBelieve is one of the world’s leading digital music companies. Believe’s mission is to develop independent artists and labels in the digital world by providing them the solutions they need to grow their audience at each...

Continue reading

CPI Aerostructures Reports Fourth Quarter and Full Year 2023 Results

CPI Aerostructures Reports Fourth Quarter and Full Year 2023 Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Fourth Quarter 2023 vs. Fourth Quarter 2022 Revenue of $23.5 million compared to $24.1 million; Gross profit of $4.1 million compared to $3.9 million; Gross margin of 17.4% compared to 16.1%; Net income of $14.8 million compared to net income of $6.8 million; Earnings per share of $1.20 ($0.09 excluding the fourth quarter 2023 deferred tax asset valuation allowance reduction of $1.11) compared to earnings per share of $0.55 ($0.03 excluding the fourth quarter 2022 deferred tax asset valuation allowance reduction of $0.52); Cash flow from operations of $3.1 million compared to $0.1 million. Full Year 2023 vs. Full Year 2022 Revenue of $86.5 million compared to $83.3 million; Gross profit of $17.1 million compared to $16.3 million; Gross margin of 19.7% compared to 19.6%; Net income of $17.2 million compared to $9.2 million; Earnings...

Continue reading

AMC Networks Announces Early Results of Tender Offer for Any and All 4.75% Senior Notes due 2025

AMC Networks Announces Early Results of Tender Offer for Any and All 4.75% Senior Notes due 2025

Written by Customer Service on . Posted in Public Companies.

NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) — AMC Networks Inc. (Nasdaq: AMCX) (the “Company”) announced the early results, as of 5:00 p.m. New York City time, on April 5, 2024 (the “Early Tender Date”) of its previously announced cash tender offer (the “Offer”) to purchase any and all of its outstanding 4.75% Senior Notes due 2025 (the “Notes”). The terms and conditions of the Offer are described in an Offer to Purchase, dated March 25, 2024 (the “Offer to Purchase”), which was previously distributed to holders of the Notes. As set forth in the Offer to Purchase, the Company reserves the right to (i) waive any and all conditions to the Offer as permitted by law, (ii) extend or terminate the Offer or (iii) otherwise amend the Offer. The following table sets forth certain terms of the Offer and the aggregate principal amount of Notes...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.